CN120225518A - Ahr激动剂 - Google Patents

Ahr激动剂 Download PDF

Info

Publication number
CN120225518A
CN120225518A CN202380078645.4A CN202380078645A CN120225518A CN 120225518 A CN120225518 A CN 120225518A CN 202380078645 A CN202380078645 A CN 202380078645A CN 120225518 A CN120225518 A CN 120225518A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
mixture
acceptable salt
stereoisomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380078645.4A
Other languages
English (en)
Chinese (zh)
Inventor
M·贝尔
J·卡尔文
C·卡森
L·绍维涅-海因斯
C·克拉克
F·多尔西
D·格纳特
S·格林
W·麦克米伦
A·纳瓦罗
J·里佐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN120225518A publication Critical patent/CN120225518A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202380078645.4A 2022-11-15 2023-11-03 Ahr激动剂 Pending CN120225518A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263425442P 2022-11-15 2022-11-15
US63/425,442 2022-11-15
PCT/US2023/078633 WO2024107555A1 (en) 2022-11-15 2023-11-03 Ahr agonists

Publications (1)

Publication Number Publication Date
CN120225518A true CN120225518A (zh) 2025-06-27

Family

ID=89121650

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380078645.4A Pending CN120225518A (zh) 2022-11-15 2023-11-03 Ahr激动剂

Country Status (17)

Country Link
US (1) US20240199608A1 (https=)
EP (1) EP4619401A1 (https=)
JP (2) JP7577819B2 (https=)
KR (1) KR20250083557A (https=)
CN (1) CN120225518A (https=)
AR (1) AR131070A1 (https=)
AU (1) AU2023382389A1 (https=)
CL (1) CL2025001421A1 (https=)
CO (1) CO2025005456A2 (https=)
CR (1) CR20250175A (https=)
DO (1) DOP2025000111A (https=)
IL (1) IL320832A (https=)
JO (1) JOP20250109A1 (https=)
MX (1) MX2025005566A (https=)
PE (1) PE20251588A1 (https=)
TW (2) TW202523664A (https=)
WO (1) WO2024107555A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025240124A1 (en) * 2024-05-14 2025-11-20 Eli Lilly And Company Processes for preparing enantiomeric compounds and related molecules
CN120904199B (zh) * 2025-09-30 2026-03-06 上海泽德曼医药科技有限公司 具有稠环结构的化合物及其在医药上的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2510528A1 (de) * 1975-03-11 1976-09-23 Hoechst Ag Benzimidazo-/1,2-a/-chinoline und verfahren zu ihrer herstellung
NL7709746A (nl) * 1976-09-09 1978-03-13 Hoechst Ag Werkwijze ter bereiding van benzimidazo-(1,2-a)-chi- nolinen.
IE52670B1 (en) 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
CN1149214C (zh) 1998-12-04 2004-05-12 东丽株式会社 三唑并衍生物和含有它们作为有效组分的趋化因子抑制剂
ATE463482T1 (de) 2002-07-25 2010-04-15 Janssen Pharmaceutica Nv Chinolinderivate und deren verwendung als mycobakterielle inhibitoren
AU2004220176A1 (en) * 2003-03-14 2004-09-23 Astrazeneca Ab Novel fused triazolones and the uses thereof
JP2007506788A (ja) * 2003-09-26 2007-03-22 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｈｃｖ感染阻害剤とその使用法
PL1753427T3 (pl) * 2004-05-28 2008-09-30 Janssen Pharmaceutica Nv Zastosowanie podstawionych pochodnych chinoliny do leczenia chorób wywoływanych przez prątki lekooporne
WO2007074491A1 (en) 2005-12-28 2007-07-05 Universita Degli Studi Di Siena HETEROTRICYCLIC AMIDE DERIVATIVES AS NEUROKININ-l (NKl) RECEPTOR LIGANDS
WO2008014307A2 (en) 2006-07-26 2008-01-31 Novartis Ag Inhibitors of undecaprenyl pyrophosphate synthase
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
WO2018171602A1 (zh) 2017-03-21 2018-09-27 正大天晴药业集团股份有限公司 用于ido和tdo双重抑制剂的脲类化合物
US12312337B2 (en) * 2019-05-10 2025-05-27 Antidote Ip Holdings, Llc Compounds and methods for treating cancer
AR126963A1 (es) * 2021-09-13 2023-12-06 Lilly Co Eli Agonistas de ahr

Also Published As

Publication number Publication date
PE20251588A1 (es) 2025-06-16
KR20250083557A (ko) 2025-06-10
TW202523664A (zh) 2025-06-16
AR131070A1 (es) 2025-02-12
IL320832A (en) 2025-07-01
US20240199608A1 (en) 2024-06-20
JP2025032072A (ja) 2025-03-11
TW202434583A (zh) 2024-09-01
JOP20250109A1 (ar) 2025-05-13
WO2024107555A1 (en) 2024-05-23
CL2025001421A1 (es) 2025-08-18
DOP2025000111A (es) 2025-06-15
EP4619401A1 (en) 2025-09-24
JP7577819B2 (ja) 2024-11-05
AU2023382389A1 (en) 2025-05-15
JP2024072283A (ja) 2024-05-27
CO2025005456A2 (es) 2025-05-19
CR20250175A (es) 2025-05-27
TWI870104B (zh) 2025-01-11
MX2025005566A (es) 2025-06-02

Similar Documents

Publication Publication Date Title
US7259165B2 (en) Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
US9688654B2 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
JP2019520396A (ja) Ｒｏｃｋ阻害剤としてのスピロ縮合環尿素
US12479845B2 (en) Imidazopyridine derivative compounds and use of same
AU2020216034B2 (en) Imidazopyridine derivative compounds and use of same
JP2009541241A (ja) オキソ置換イミダゾ［１，２ｂ］ピリダジン、その調製方法、及び医薬としての使用
US6194428B1 (en) Use of 5-substituted pyridine and hexahydroquinoline-3 carboxylic acid derivatives for treating diseases of the central nervous system
CN120225518A (zh) Ahr激动剂
FR2563521A1 (fr) Derives de la 1,4-dihydro-4-oxonaphtyridine et leurs sels, procede pour leur production et agents antibacteriens les contenant
US7608717B2 (en) Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands
AU2013276165B2 (en) Tricyclic compounds as KAT II inhibitors
CN117769556A (zh) 嘧啶并环类衍生物及其制备方法和用途
RU2596823C2 (ru) ПРОИЗВОДНЫЕ 7-(ГЕТЕРОАРИЛ-АМИНО)-6,7,8,9-ТЕТРАГИДРОПИРИДО[1,2-a]ИНДОЛ-УКСУСНОЙ КИСЛОТЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА ПРОСТАГЛАНДИНА D2
EP2185558B1 (fr) Dérivés de n-hétéroaryl-carboxamides tricycliques, leur préparation et leur application en thérapeutique
JP2024539213A (ja) アリール又はヘテロアリール誘導体及びこれを有効成分として含むキナーゼ関連疾患の予防又は治療用薬学的組成物
TW201315731A (zh) 菸鹼乙醯膽鹼受體之新穎正向異位調節劑
JP7333420B2 (ja) トリアゾロピリミジン化合物及びその塩、組成物と使用
CN111410648A (zh) 一种手性c-KIT抑制剂药物关键中间体及其制备方法
CN118215655A (zh) Ahr激动剂
JP3354526B2 (ja) トロバフロキサシン酸塩の製造方法
CN121941683A (zh) 含氮并环类化合物、其药物组合物及其应用
US9321766B1 (en) Kinase inhibitors
JP2010534231A (ja) デュシェンヌ型筋ジストロフィーを治療するための化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination